ATB200/AT2221: Phase 1/2 Safety Study (ATB200-02 Study)
Open-label, Dose-escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenous ATB200 Co-administered with Oral AT2221 in Patients with Pompe Disease
Ongoing, currently recruiting patients 18 to 65 years with a diagnosis of Pompe disease.
Open-label, dose-escalation study of Pompe disease patients to assess if the co-administration of investigational new drugs ATB200 and AT2221 is safe in adults with Pompe disease.
More information: www.clinicaltrials.gov: NCT02675465